Dr. Gilmour came to RTI in 2004 after working at Cogent Neurosciences Inc., an early stage drug discovery company. While at Cogent, he established their molecular biology capabilities and optimized and validated multiple high-throughput biological assays as director of neurogenomics. At RTI, he manages the molecular biology and assay development group. While providing the resources and expertise to perform and interpret cell-based assays, this group is involved in designing, developing, and validating additional assays. Their current focus is on screening and characterization assays for ligands of GPCRs and ion channels. The techniques they use include radioligand-binding assays, FLIPR-based calcium and membrane potential assays, GTP exchange assays, and high-content automated fluorescence imaging.
PhD, Biochemistry, Dartmouth Medical School; BS, Biology, Furman University